L26/P-714 Modified clomiphene citrate protocol yields an equivalent cumulative clinical pregnancy rate at a lower drug cost without prolonging the time: a propensity score-matched cohort study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1042 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von X. Shen und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does a modified Clomiphene Citrate (CC) protocol achieve a comparable cumulative clinical pregnancy rate (CCPR) as a GnRH-antagonist protocol, and what is its economic impact? Summary answer The modified CC protocol yields an equivalent CCPR and time to clinical pregnancy (TTCP) but reduces drug costs by over 80% and demonstrates superior cost-effectiveness. What is known already Although the gonadotropin-releasing hormone (GnRH) antagonist protocol is a standard regimen valued for reliably preventing premature LH surges, CC, a selective estrogen receptor modulator offering oral administration and low cost, has traditionally been limited to mild stimulation in poor-prognosis patients due to concerns about its anti-estrogenic effects on the endometrium and lower oocyte yield. While a modified protocol combining CC with adequate-dose gonadotropin aims to balance efficacy and cost, robust comparative studies against the GnRH-antagonist protocol in a general IVF population are lacking, particularly those evaluating comprehensive endpoints like CCPR, TTCP, and detailed cost-effectiveness. Study design, size, duration This was a retrospective cohort study conducted at a single reproductive centre from January 2022 to August 2025. To minimize selection bias, 1:1 propensity score matching was performed using key prognostic factors, including female age, anti-Müllerian hormone (AMH), antral follicle count (AFC), and basal follicle-stimulating hormone (FSH). The final matched analysis included 929 pairs undergoing IVF/ICSI cycles. Participants/materials, setting, methods Infertile patients at a single reproductive centre were included. The CC group received oral CC (100-150mg daily from cycle day 2/3) combined with individualized gonadotropin (initial dose: 100-450 IU/day). The GnRH-antagonist group received a conventional GnRH-antagonist protocol with gonadotropin based on the same individualization criteria. Primary outcomes were CCPR and TTCP. A decision tree model mapped treatment pathways. Cost-effectiveness analysis calculated the cost per cumulative clinical pregnancy and the incremental cost-effectiveness ratio (ICER). Main results and the role of chance The CCPR was nearly identical between the two protocols (CC: 51.60% vs. GnRH-antagonist: 51.79%, P = 1.000). The median TTCP was 3.0 months in both groups, with no significant difference in the probability of clinical pregnancy over time (Hazard Ratio=0.95, P = 0.58). The clinical pregnancy rate after the first frozen embryo transfer (FET) was numerically higher in the CC group, though not statistically significant (46.4% vs. 40.9%, P = 0.098). Decision tree analysis revealed fundamentally different treatment strategies in the two groups. A near-universal “freeze-all” approach was adopted in the CC group (fresh transfer rate 0.1%), compared to a fresh transfer rate of 23.6% in the GnRH-antagonist group (P < 0.001). The total drug cost per stimulation cycle was reduced by over 80% with the CC protocol (CC: ¥1,414.70 vs. GnRH-antagonist: ¥7,266.24). Consequently, the cost per cumulative clinical pregnancy achieved was markedly lower for the CC protocol (CC: ¥2,741.44 vs. GnRH-antagonist: ¥14,031.36). The resulting ICER was ¥3,225,122.47 per additional cumulative clinical pregnancy gained with the GnRH-antagonist protocol, indicating that the modified CC protocol is the dominant strategy, offering substantial cost savings without compromising ultimate reproductive success. Limitations, reasons for caution The retrospective, single-center design may have residual confounding. The primary endpoint was cumulative clinical pregnancy, as cumulative live birth data were unavailable. Cost savings are specific to the Chinese healthcare context, and findings require external validation in other settings. Wider implications of the findings The modified CC protocol yields equivalent CCPR without prolonging the TTCP, while drastically reducing drug costs. Its cost-effectiveness dominance offers a compelling strategy to alleviate the significant financial burden of IVF, making effective treatment more accessible. Trial registration number No
Zitieren
APA
Shen, X., & Zhu, W. (2026). L26/P-714 Modified clomiphene citrate protocol yields an equivalent cumulative clinical pregnancy rate at a lower drug cost without prolonging the time: a propensity score-matched cohort study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1042
Vancouver
Shen X, Zhu W. L26/P-714 Modified clomiphene citrate protocol yields an equivalent cumulative clinical pregnancy rate at a lower drug cost without prolonging the time: a propensity score-matched cohort study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1042
BibTeX
@article{Shen2026,
author = {Shen, X. and Zhu, W.},
title = {L26/P-714 Modified clomiphene citrate protocol yields an equivalent cumulative clinical pregnancy rate at a lower drug cost without prolonging the time: a propensity score-matched cohort study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1042}
}
EUVIMED